Single or Repeat Dose of G03-52-01 in Adult Subjects
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of G03-52-01 in Adult Subjects
Sponsor: U.S. Army Medical Research and Development Command
Listed as NCT05348993, this PHASE2 trial focuses on Botulinum Toxin and Healthy and remains completed. Sponsored by U.S. Army Medical Research and Development Command, it has been updated 10 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE2
-
Oct 2025 — Feb 2026 [monthly]
Completed PHASE2
-
Mar 2025 — Oct 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Nov 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
▶ Show 5 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Aug 2023 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Aug 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- U.S. Army Medical Research and Development Command
- United States Department of Defense
For direct contact, visit the study record on ClinicalTrials.gov .